Výsledky vyhledávání

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

An induction dose of epoetin α of 40 000 IU daily for three consecutive days increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy

Autor: C. Dellach, M. L. Leita, Giorgio Mustacchi, R. Ceccherini, S Foladore, M Sisto, S. Milani

Publikováno v: Annals of Oncology. 17:1705-1708

Background: This pilot study was conducted to evaluate the feasibility, activity, and safety of an induction dose of epoetin α in cancer patients with moderate or severe anemia who were receiving chemotherapy. Patients and methods: Thirty patients w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dadbfb260435b3794fcd9dfaf6a719de
https://doi.org/10.1093/annonc/mdl297

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

An induction dose of epoietin alpha of 40.000 IU daily for three consecutive days increases and mantains hemoglobin levels in anemic cancer patients undergoing chemotherapy

Autor: MUSTACCHI, GIORGIO, R. CECCHERINI, C. DELLACH, S. FOLADORE, S. MILANI, M. LEITA AND M. SISTO

Background: This pilot study was conducted to evaluate the feasibility, activity, and safety of an induction dose of epoetin a in cancer patients with moderate or severe anemia who were receiving chemotherapy. Patients and methods: Thirty patients wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::c411ab1c31e1010961557316e1407137
http://hdl.handle.net/11368/2290954

Zobrazit plný text záznamu

Multidrug Chemotherapy in the Treatment of Non-Elderly Patients with Hormone-Refractory Prostatic Carcinoma

Autor: A. Veronesi, G. Lo Re, S. Foladore, A. Merlo, N. Giuliotto, R. Talamini, S. Monfardini, null within the North-Eastern Italian Oncology Group (GOCCNE)

Publikováno v: European Urology. 29:434-438

Objective : The effectiveness of a chemotherapy regimen including cisplatin, epirubicin, and estramustine phosphate was evaluated in a series of young patients with prostate cancer. Methods : 28 patients with a histological diagnosis of prostatic car

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::95c2c0811644d96661e66fd81f0b9183
https://doi.org/10.1159/000473792

Zobrazit plný text záznamu

Cisplatin and etoposide versus cyclophosphamide, epirubicin and vincristine in small cell lung cancer: a randomised study

Autor: G. Cartel, O. Nascimben, S. Foladore, S. Monfardini, M.Delia Valentina, M. D. Magri, D. CriveUari, A. Sibau, Marco Trovo, Andrea Veronesi, R. Talamini

Publikováno v: European Journal of Cancer. 30:1474-1478

From September 1986 until December 1991, 139 patients with histologically-proven small cell lung cancer, age 40, absence of brain metastases and no previous treatment, were randomised to receive either CEV cyclophosphamide 1000 mg/m2 intravenous (i.v

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba2beba5285508f0364ef0c31727fbf3
https://doi.org/10.1016/0959-8049(94)00253-2

Zobrazit plný text záznamu

Buserelin treatment of advanced prostatic carcinoma: prognostic factor analysis

Autor: V. Dal Bo, Andrea Veronesi, R. Talamini, S. Foladore, S. Monfardini, M. Francini, Silvia Franceschi, G. Lo Re, P. Belmonte, B. Ciaccio

Publikováno v: European urology. 21(4)

From August 1986 to August 1990, 116 patients with prostatic carcinoma, advanced disease (stage C-D1 only in patients older than 75 years, or D2) were treated with Buserelin (0.5 mg 3 times/day subcutaneously for 7 days, followed by 0.4 mg 3 times/da

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a186bf09df6442a115d2eda84f786188
https://pubmed.ncbi.nlm.nih.gov/1459148

Zobrazit plný text záznamu

Treatment patterns in elderly patients (greater than or equal to 70 years) with breast carcinoma. A retrospective study of the Gruppo Oncologico Clinico Cooperativo del nord-Est (GOCCNE)

Autor: D, Crivellari, E, Galligioni, S, Foladore, D, Errante, G, Conte, O, Nascimben, M, Amichetti, P, Spagnolli, E, Recaldin, A, Grandinetti

Publikováno v: Tumori. 77(2)

The pattern of treatment used in elderly women affected by breast carcinoma was evaluated in a retrospective study by the North-East Clinical Cooperative Group in Italy (GOCCNE). Six divisions were involved in the study. The medical records of 115 el

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::49445b9b1263b50cd9d2a8c2d2cefc65
https://pubmed.ncbi.nlm.nih.gov/2048225

Zobrazit plný text záznamu

Epirubicin in the treatment of malignant mesothelioma: a phase II cooperative study. The North-Eastern Italian Oncology Group (GOCCNE)--Mesothelioma Committee

Autor: M D, Magri, A, Veronesi, S, Foladore, D, De Giovanni, C, Serra, F, Crismancich, G, Tuveri, M, Nicotra, M, Tommasi, S, Morassut

Publikováno v: Tumori. 77(1)

From September 1986 to April 1988, all consecutive patients with histologically proven (pathologic review mandatory) malignant mesothelioma, measurable disease, age less than 75 years, Karnofsky performance status equal to or greater than 40, and no

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::6f98d839453ec1fcbf520b48c7885a23
https://pubmed.ncbi.nlm.nih.gov/2017799

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání